To investigate the transcriptomic changes in immune cells following nasal Foralumab treatment in SARS-CoV-2-infected patients, we Fluorescence-activated cell sorting (FACS)sorted CD3+ (T cells), CD19+ (B cells), and CD14+ (monocytes) cells from Foralumab-treated and untreated COVID-19 patients at baseline (day -2) and day 10 as well as in healthy subjects (Fig. 1A and SI Appendix, Fig. S1 A, B and Table S1)(PRJNA899867 and PRJNA890877). This evidence concerns the gene CD19 and COVID-19.